Zobrazeno 1 - 10
of 150
pro vyhledávání: '"M S, Czuczman"'
Autor:
T, Hahn, M, Benekli, C, Wong, K B, Moysich, A, Hyland, A M, Michalek, A, Alam, M R, Baer, B, Bambach, M S, Czuczman, M, Wetzler, J L, Becker, P L, McCarthy
Publikováno v:
Bone Marrow Transplantation. 35:557-566
There are several prognostic models for Hodgkin's disease (HD) patients, but none evaluating patient characteristics at time of blood and marrow transplantation (BMT). We developed a prognostic model for event-free survival (EFS) post-BMT based on HD
Autor:
M S, Czuczman
Publikováno v:
Anti-cancer drugs. 12
Rituximab is a human-mouse chimeric monoclonal antibody that has demonstrated efficacy against non-Hodgkin's lymphoma (NHL). There is a powerful rationale for combining rituximab treatment with chemotherapeutic agents that have also shown efficacy in
Autor:
M S, Czuczman
Publikováno v:
Seminars in oncology. 26(5 Suppl 14)
Indolent (low-grade) B-cell lymphomas are responsive to single-agent and combination chemotherapy agents, but unfortunately possess an incurable, relapsing nature. Novel agents and innovative treatment approaches need to be evaluated in these patient
Autor:
M S, Czuczman, R K, Dodge, C C, Stewart, S R, Frankel, F R, Davey, B L, Powell, T P, Szatrowski, C A, Schiffer, R A, Larson, C D, Bloomfield
Publikováno v:
Blood. 93(11)
The prognostic value of immunophenotype in adult acute lymphoblastic leukemia (ALL) has varied based on the methods used, surface markers studied, and therapy administered. From April 1991 to September 1996, samples of leukemic marrow or blood from 2
Publikováno v:
Leukemia. 7(7)
JD118 is a murine immunoglobulin M monoclonal antibody (mAb) under study as a therapeutic agent that is capable of potent human complement-mediated cytotoxicity (CMC) against B-cell lymphoma and leukemia targets. The JD118 antigen target was upregula
Autor:
M. S. Czuczman, J. Vose, P. Zinzani, C. Reeder, R. Buckstein, C. Haioun, R. Bouabdallah, J. Polikoff, A. Ervin-Haynes, T. Witzig
Publikováno v:
Journal of Clinical Oncology. 27:e19504-e19504
e19504 Background: Patients with diffuse large-B-cell lymphoma (DLBCL) who are not cured with R-CHOP or high-dose chemotherapy with autologous stem cell rescue have a dismal prognosis. A recent phase II trial (NHL-002) of lenalidomide in patients wit
Publikováno v:
Journal of Clinical Oncology. 22:2502-2502
Autor:
Miebach, Lea1,2 (AUTHOR), Melo‐Zainzinger, Gabriella2,3 (AUTHOR), Freund, Eric1,2,4 (AUTHOR), Clemen, Ramona2 (AUTHOR), Cecchini, Alessandra Lourenco5 (AUTHOR), Bekeschus, Sander2,6 (AUTHOR) sander.bekeschus@inp-greifswald.de
Publikováno v:
Advanced Science. Oct2023, Vol. 10 Issue 28, p1-16. 16p.
Autor:
Lee, Kevin K., Chakraborty, Mou, Hu, Aohan, Kanagasundaram, Thines, Thorek, Daniel L. J., Wilson, Justin J.
Publikováno v:
Dalton Transactions: An International Journal of Inorganic Chemistry; 9/21/2024, Vol. 53 Issue 35, p14634-14647, 14p